Pricing Log in Create free account
Friday 6 November 2026 Export PRVA’s income statement to Excel — free account

Privia Health Group, Inc.

PRVA Healthcare Health Information Services

Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.

Revenue
+13.2%
EPS
+83.3%
Free cash flow
−44.4%

Quarter to September 2026, against a year earlier

24.40 0.46 +1.92%
Market cap
$3.1B
P/E
88.3×
Fwd P/E
83.4×
Dividend yield
—
F-score
6/9
Altman Z
4.78
Beneish M
−2.59
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 22.24
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 — 2 8 1 4 3 4 — — — —
Insider Ownership 6.97%

Capital & Financial Ratios $m

Size
Market Cap 3,060.00
Revenue ttm 2,434.61
Net income ttm 38.62
Free cash flow ttm 108.07
Net debt Q (446.28)
Valuation
P/E 88.26 (above 35: high)
Forward P/E 83.40 (above 35: high)
Price / sales 1.25
Forward P/S Powerpack
Price / FCF 28.20
Price / book 3.48
Financial health
Current ratio Q 1.63 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (1.72)
Growth
Revenue growth Q +13.19% (above 0%: growing)
Operating income growth Q +42.62% (above 0%: growing)
EPS, this year +50.42% (at or above 15%: strong)
EPS, next year A +61.58% (at or above 15%: strong)
Revenue, next year A +15.79% (at or above 10%: strong)
EPS, past 5 yrs −10.99% (below 0%: weak)
EPS, next 5 yrs A +47.19% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.1×, against a ten-year median of 1.4×; over the ten years it ranged from 0.9× in 2026 to 5.0× in 2021.
P/E against its own 10 years 12.87%
10-year low 10-year high
P/S against its own 10 years 11.16%
10-year low 10-year high
P/B against its own 10 years 16.70%
10-year low 10-year high
EV/Sales against its own 10 years 14.33%
10-year low 10-year high
EV/FCF against its own 10 years 39.60%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 390 491 480 446
Receivables 291 316 401 624
Inventory — — — —
Other — — — —
701 835 911 1,100
2023 2024 2025 Q'26
Payables 58 82 97 100
ST’ Debt — — — —
Other 326 365 470 572
387 449 569 674

Compound Annual Growth %

10y 5y 3y
Sales — 21.04% 16.10%
Cash Flow — 33.25% 51.28%
Earnings — (6.01%) 0.00%
Book Value — 40.66% 15.07%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.08 Actual 0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.06 0.05 Miss by 0.01
Q4 FY25 0.04 0.07 Beat by 0.03
Q1 FY26 0.08 0.02 Miss by 0.06
Q2 FY26 0.08 0.07 Miss by 0.01
Q3 FY26 0.09 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.02 0.07 0.11 — —
’25 0.03 0.02 0.05 0.07 0.18
’24 0.02 0.03 0.03 0.03 0.11
’23 0.06 0.06 0.05 0.02 0.19
’22 (0.16) (0.10) 0.01 0.14 (0.08)
’21 0.06 (1.68) (0.09) (0.11) (1.83)
’20 0.06 0.05 0.17 0.04 0.32
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 604 633 657 — —
’25 480 521 580 541 2,123
’24 415 422 438 461 1,736
’23 386 413 417 441 1,658
’22 314 336 343 364 1,357
’21 214 226 252 275 966
’20 213 183 207 214 817
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) 1 29 — —
’25 (24) 8 52 128 163
’24 (33) 34 33 75 109
’23 (13) 8 22 64 81
’22 (5) 7 16 29 47
’21 (2) 7 63 (12) 55
’20 (7) 14 36 (3) 39
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) 1 29 — —
’25 (24) 8 52 128 163
’24 (33) 34 33 75 109
’23 (13) 8 22 64 81
’22 (5) 7 16 29 47
’21 (2) 7 62 (12) 55
’20 (7) 13 36 (3) 39
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 658 786 817 966 1,357 1,658 1,736 2,123 2,435 +18.2% 2,458 2,698 3,028 +12.6%
Gross margin, % — — 8.36 8.71 10.11 6.59 9.93 9.74 10.19 9.87 0.00 +1.5 pt
EBT — — (4) 9 23 (219) (19) 29 28 44 62 n/m
EBT margin, % — — (0.61) 1.16 2.87 (22.61) (1.37) 1.75 1.61 2.07 2.53 +2.7 pt
Net income — 0 (3) 8 31 (191) (12) 21 17 30 39 n/m
Per share, $
Per share, $ Revenue — — 6.21 8.20 8.52 9.39 12.26 14.20 14.54 17.38 19.09 +15.8%
Earnings — — (0.03) 0.08 0.32 (1.83) (0.08) 0.20 0.12 0.19 0.27 n/m
Cash flow — — 0.05 0.25 0.41 0.53 0.43 0.69 0.92 1.34 0.85 +60.1%
Capex — — 0.00 (0.06) 0.00 (0.01) 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow — — 0.05 0.19 0.40 0.53 0.43 0.69 0.92 1.34 0.85 +60.1%
Book value — — 0.00 0.00 1.50 4.37 4.69 5.20 5.72 6.47 6.84 n/m
Shares, m — — 106 96 96 103 111 117 119 122 125 +2.0%
Valuation, ×
Valuation, × P/E — — 70.42 70.42 70.42 0.00 0.00 124.79 150.38 131.72 88.26 77.3
P/S — — 2.70 2.70 2.70 2.76 1.82 1.67 1.34 1.36 1.25 2.1
P/B — — 14.78 14.78 14.78 5.92 4.75 4.56 3.42 3.66 3.48 8.3
EV/Sales — — 2.64 2.64 2.64 2.46 1.59 1.45 1.08 1.15 1.08 2.0
EV/FCF — — 50.05 50.05 50.05 43.56 45.67 29.94 17.20 15.01 24.35 37.7
Cash, $m
Cash, $m Operating cash flow — — 5 24 39 55 47 81 109 163 108 +63.4%
Capex — — 0 (6) 0 (1) 0 0 — — 0 (12.5%)
Free cash flow — — 5 19 39 55 47 81 109 163 108 +63.4%
Balance, $m
Balance, $m Working capital — — — 14 43 256 288 314 386 342 425 +69.6%
Net debt — — — (7) (52) (289) (348) (390) (491) (480) (446) +101.5%
Shareholders’ equity — — — — 144 450 519 607 683 791 873 +40.7%
Returns, %
Returns, % ROA — — 0.00 0.00 19.00 (37.08) (1.16) 2.57 1.35 1.83 2.38 +1.8 pt
ROIC — — — 0.00 17.28 (84.26) (6.99) 5.92 5.52 6.87 7.47 +6.9 pt
ROE — — 0.00 6.42 24.61 (63.39) (1.77) 4.10 2.23 3.11 4.25 +3.1 pt
People
People Employees — — — — 559 810 964 1,102 1,140 1,226 — +17.0%
Revenue/emp, $m — — 0.00 0.00 1.46 1.19 1.41 1.50 1.52 1.73 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Privia Health Group, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DOCS Doximity, Inc. $5.9B 44.4× 49.7× +3.57% (above 0%: growing) −42.42% (below 0%: shrinking) +1.87% (above 0%: growing) 85.48% 25.16% Compare
WAY Waystar Holding Corp. $5.6B 40.9× 31.9× +21.21% (above 0%: growing) −10.22% (below 0%: shrinking) +23.36% (above 0%: growing) 69.53% 18.81% Compare
HTFL Heartflow, Inc. $4.5B — (loss-making) — (loss-making) +47.57% (above 0%: growing) n/m +62.62% (above 0%: growing) 83.00% (27.93%) Compare
PRVA Privia Health Group, Inc. $3.1B 88.3× 83.4× +13.19% (above 0%: growing) +83.33% (above 0%: growing) −44.35% (below 0%: shrinking) 0.00% 3.13%
SDGR Schrodinger, Inc. $2.2B — (loss-making) — (loss-making) +18.72% (above 0%: growing) n/m +21.64% (above 0%: growing) 59.32% (40.52%) Compare
CERT Certara, Inc. $1.9B — (loss-making) — (loss-making) −9.29% (below 0%: shrinking) +300.00% (above 0%: growing) −12.09% (below 0%: shrinking) 66.87% 2.45% Compare
OMCL Omnicell, Inc. $1.7B 39.0× 32.9× −0.89% (below 0%: shrinking) +100.50% (above 0%: growing) +42.62% (above 0%: growing) 44.77% 4.85% Compare
TDOC Teladoc Health, Inc. $1.7B — (loss-making) — (loss-making) −3.41% (below 0%: shrinking) n/m +11.76% (above 0%: growing) 68.56% (4.64%) Compare
GDRX GoodRx Holdings, Inc. $1.2B 65.7× 46.0× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79% Compare
Median of peers $2.0B 42.6× 39.5× +1.34% −10.22% +22.50% 69.05% 3.65%

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 2 April 2026

Ownership

Directors and executive officers, together 5.70%
BlackRock, Inc. 12.80%
FMR LLC 10.10%
Vanguard Group 10.00%
Durable Capital Partners 9.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Privia Health Group, Inc. (PRVA) Latest News

6 Nov

Impact 3 · · MarketBeat transcript

5 Nov

Impact 3 · · Zacks
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

2 Nov

Impact 3 · · GlobeNewswire

27 Oct

Impact 3 · · StockStory

19 Oct

Impact 3 · · StockStory

30 Sep

Impact 3 · · StockStory

19 Sep

Impact 3 ·

20 Aug

Impact 4 ·

15 Aug

Impact 3 ·

13 Aug

Impact 3 ·
Impact 3 · · The Motley Fool transcript

9 Aug

Impact 3 ·
Impact 3 ·

7 Aug

Impact 4 · · MarketBeat transcript

6 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·

5 Jun

Impact 3 · · Simply Wall St.

27 May

Impact 3 · · GlobeNewswire

14 May

Impact 3 ·

8 May

Impact 4 · · MarketBeat
Impact 4 · · Moby

7 May

Impact 4 · · Zacks
Impact 4 · · StockStory
Impact 4 · · GlobeNewswire
Impact 3 ·

23 Apr

Impact 4 · · StockStory

PRVA metrics, ten years each

stockrow.com/PRVA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com